RT Journal Article
SR Electronic
T1 Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer and coronary disease pathways
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.25.22278025
DO 10.1101/2022.07.25.22278025
A1 Wang, Lihua
A1 Western, Dan
A1 Timsina, Jigyasha
A1 Repaci, Charlie
A1 Song, Won-Min
A1 Norton, Joanne
A1 Kohlfeld, Pat
A1 Budde, John
A1 Climer, Sharlee
A1 Butt, Omar H.
A1 Jacobson, Daniel
A1 Garvin, Michael
A1 Templeton, Alan R
A1 Campagna, Shawn
A1 O’Halloran, Jane
A1 Presti, Rachel
A1 Goss, Charles W.
A1 Mudd, Philip A.
A1 Ances, Beau M.
A1 Zhang, Bin
A1 Sung, Yun Ju
A1 Cruchaga, Carlos
YR 2022
UL http://medrxiv.org/content/early/2022/07/25/2022.07.25.22278025.abstract
AB Identification of the plasma proteomic changes of Coronavirus disease 2019 (COVID-19) is essential to understanding the pathophysiology of the disease and developing predictive models and novel therapeutics. We performed plasma deep proteomic profiling from 332 COVID-19 patients and 150 controls and pursued replication in an independent cohort (297 cases and 76 controls) to find potential biomarkers and causal proteins for three COVID-19 outcomes (infection, ventilation, and death). We identified and replicated 1,449 proteins associated with any of the three outcomes (841 for infection, 833 for ventilation, and 253 for death) that can be query on a web portal (https://covid.proteomics.wustl.edu/). Using those proteins and machine learning approached we created and validated specific prediction models for ventilation (AUC>0.91), death (AUC>0.95) and either outcome (AUC>0.80). These proteins were also enriched in specific biological processes, including immune and cytokine signaling (FDR ≤ 3.72×10-14), Alzheimer’s disease (FDR ≤ 5.46×10-10) and coronary artery disease (FDR ≤ 4.64×10-2). Mendelian randomization using pQTL as instrumental variants nominated BCAT2 and GOLM1 as a causal proteins for COVID-19. Causal gene network analyses identified 141 highly connected key proteins, of which 35 have known drug targets with FDA-approved compounds. Our findings provide distinctive prognostic biomarkers for two severe COVID-19 outcomes (ventilation and death), reveal their relationship to Alzheimer’s disease and coronary artery disease, and identify potential therapeutic targets for COVID-19 outcomes.Competing Interest StatementCC has received research support from: Biogen, EISAI, Alector and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid genetics, Halia Therapeutics and ADx Healthcare.Funding StatementThis study was funded by the National Institutes of Health (RF1AG074007 (YJS) R01AG044546 (CC) P01AG003991(CC) RF1AG053303 (CC) RF1AG058501 (CC) and U01AG058922 (CC)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Washington University School of Medicine in St. Louis gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://www.niagads.org/Knight ADRC-collection https://covid.proteomics.wustl.edu/